Vfend®
Voriconazole 200 mg · oral tablet
Antifungal
Approved uses
Systemic fungal infection, this label's only approved use: invasive aspergillosis, candidemia in non-neutropenic patients and other deep tissue Candida infections, esophageal candidiasis, and serious Scedosporium apiospermum or Fusarium infection in patients intolerant of or refractory to other therapy
Adults, 200 mg orally every 12 hours as maintenance (100 mg every 12 hours below 40 kg), which may be increased to 300 mg (150 mg below 40 kg) for inadequate response; aspergillosis, candidemia and scedosporiosis or fusariosis start with intravenous loading 6 mg/kg every 12 hours for the first 24 hours.
OFF-LABELNot in the FDA label for this product
Severe filamentous fungal keratitis, oral adjunct to topical antifungals
400 mg orally every 12 hours for 24 hours, then 200 mg orally every 12 hours for 20 days, alongside topical antifungal therapy
RCT · n=240 · no benefit
MUTT II, a multicenter double-masked placebo-controlled randomized trial of 240 patients with smear-positive filamentous ulcers and vision 20/400 or worse, found no difference in corneal perforation or therapeutic penetrating keratoplasty when this oral regimen was added to topical therapy (hazard ratio 0.82, 95% CI 0.57 to 1.18, P=0.29), with 58 adverse events (48.7%) versus 28 (23.1%) on placebo, P<0.001; the authors concluded there appears to be no benefit. In the earlier phase 3 MUTT I trial of 323 patients, compounded topical voriconazole 1% was inferior to topical natamycin 5% on 3-month best corrected acuity (regression coefficient 0.18 logMAR favoring natamycin, P=0.006) and on perforation or keratoplasty (odds ratio 0.42 favoring natamycin, 95% CI 0.22 to 0.80, P=0.009), with the difference driven by Fusarium cases.
Contraindications
- Hypersensitivity to voriconazole or its excipients
- Concomitant drugs highly dependent on CYP3A4 for metabolism whose elevated plasma concentrations are associated with serious and/or life-threatening reactions (eplerenone, ergot alkaloids, finerenone, ivabradine, lurasidone, naloxegol, pimozide, quinidine, rifabutin, sirolimus, tolvaptan, venetoclax at CLL or SLL initiation and ramp-up, voclosporin)
- Concomitant drugs and herbal products that induce CYP2C19, CYP2C9 and/or CYP3A4, whose reduced voriconazole plasma concentrations may be associated with loss of efficacy (carbamazepine, long-acting barbiturates, rifampin, rifabutin, efavirenz 400 mg or more every 24 hours, high-dose ritonavir 400 mg every 12 hours, St. John's Wort)
50 mg and 200 mg tablets, bottles of 30
Azole antifungal that inhibits fungal cytochrome P-450 mediated 14 alpha-lanosterol demethylation, an essential step in ergosterol biosynthesis. Accumulation of 14 alpha-methyl sterols with subsequent loss of ergosterol may account for the antifungal activity. Isolates with reduced susceptibility to fluconazole or itraconazole may also show reduced susceptibility to voriconazole, suggesting cross-resistance can occur among these azoles.
Warnings & Precautions
- Visual disturbances: Effect on visual function past 28 days of treatment is unknown, and postmarketing reports include prolonged reactions such as optic neuritis and papilledema. Monitor visual acuity, visual field and color perception if treatment continues beyond 28 days.
- Hepatic toxicity: Uncommon serious reactions (clinical hepatitis, cholestasis, fulminant hepatic failure including fatalities), mostly in patients with serious underlying conditions; hepatitis and jaundice occurred without other identifiable risk factors. Measure transaminases and bilirubin at initiation, at least weekly for the first month, then monthly if no clinically significant changes; discontinue if liver function tests are markedly elevated compared to baseline unless benefit/risk justifies continued use.
- QT prolongation and arrhythmias: Rare cases of arrhythmias including torsade de pointes, cardiac arrests and sudden deaths, usually in seriously ill patients with multiple confounding risk factors. Use with caution in potentially proarrhythmic conditions such as congenital or acquired QT prolongation, cardiomyopathy (in particular with heart failure), sinus bradycardia, symptomatic arrhythmias or drugs known to prolong the QT interval. Correct potassium, magnesium and calcium before and during therapy.
- Infusion related reactions: Anaphylactoid-type reactions, including flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus and rash, have occurred uncommonly in healthy subjects during intravenous infusion, starting immediately; consider stopping the infusion if they occur.
- Severe cutaneous adverse reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS, which can be life threatening or fatal; discontinue if one develops.
- Photosensitivity: Voriconazole has been associated with photosensitivity skin reactions; avoid direct sunlight, use protective clothing and high-SPF sunscreen, and refer phototoxic reactions to a dermatologist and consider stopping. Squamous cell carcinoma (including Bowen's disease) and melanoma have been reported in long-term therapy in patients with photosensitivity; discontinue if a premalignant lesion, squamous cell carcinoma or melanoma develops. Phototoxicity is more frequent in pediatric patients.
- Renal toxicity: Acute renal failure has been observed, and patients are likely to be on concomitant nephrotoxic medications; monitor renal function, including serum creatinine.
- Adrenal dysfunction: Reversible cases of adrenal insufficiency have been reported, and adrenal insufficiency has been reported with or without concomitant corticosteroids; Cushing's syndrome has been reported with corticosteroids. Monitor patients on corticosteroids by any route for adrenal dysfunction during and after treatment. Instruct patients to seek immediate medical care if they develop signs and symptoms of Cushing's syndrome or adrenal insufficiency.
- Pancreatitis: Observed during treatment; monitor patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) for its development.
- Skeletal adverse reactions: Fluorosis and periostitis with long-term therapy; discontinue if skeletal pain with compatible radiologic findings appears.
- Embryo-fetal toxicity: Voriconazole can cause fetal harm; in animals it was associated with fetal malformations, embryotoxicity, increased gestational length, dystocia and embryomortality. Inform a patient who is or becomes pregnant of the potential hazard, and advise females of reproductive potential to use effective contraception.
- Clinically significant drug interactions: Some drugs may alter voriconazole concentrations, and voriconazole may interact with other drugs and alter their pharmacokinetics or pharmacodynamics; increase the maintenance dose when coadministered with phenytoin or efavirenz.
- Galactose intolerance: Tablets contain lactose and are not for patients with hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Common Side Effects
The most frequent adverse reactions in adult trials were visual disturbances (18.7%), fever (5.7%), nausea (5.4%), rash (5.3%), vomiting (4.4%), chills (3.7%), headache (3.0%), liver function test increased (2.7%), tachycardia (2.4%) and hallucinations (2.4%). About 21% had abnormal vision, color vision change and/or photophobia, which may be associated with higher plasma concentrations and/or doses. In healthy subjects, 28 days of dosing decreased ERG amplitude and the visual field and altered color perception, all normal fourteen days after dosing ended. Optic neuritis, papilledema, optic atrophy, keratitis, uveitis and retinal hemorrhage occurred in under 2%. Transaminases rose above 3 times the upper limit of normal in 17.7% of adults in pooled trials (not necessarily an adverse reaction). Elevated liver function tests, rash and visual disturbances most often led to discontinuation.
Pregnancy: Can cause fetal harm and there are no human data. Cleft palate and hydronephrosis or hydroureter occurred in rats at and above 0.3 times the recommended maintenance dose by body surface area, and embryomortality with reduced fetal weight occurred in rabbits at 6 times that dose.
Lactation: No data on presence in human milk, on effects in the breastfed infant, or on milk production.
Established from 2 years of age; not recommended below 2 years.